Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis-Reference-Cited by-同舟云学术

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

Published:2023-07 Issue: Volume:75 Page:104733
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Boldrini Vinícius Oliveira^ORCID,Mader Simone,Kümpfel Tania,Meinl Edgar^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference19 articles.

1. Neutralizing antibodies and antidrug antibodies in the ublituximab phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis;Alvarez;Mult. Scler. J.,2022

2. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study;Bar-Or;Mult. Scler. J.,2022

3. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies;Dunn;Mult. Scler. J.,2018

4. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II;Gärtner;Mult. Scler. J.,2022

5. Ofatumumab versus teriflunomide in multiple sclerosis;Hauser;N. Engl. J. Med.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B‑lymphocyte‑targeted MS therapy: from theory to a decade of ocrelizumab in practice;Neurologie pro praxi;2024-04-16

2. Pregnancy and reproductive health in women with multiple sclerosis: an update;Current Opinion in Neurology;2024-04-08

3. Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy;Revue Neurologique;2024-04